ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News. A product of MS Views and News, a Not-for-Profit [501c3] organization. Founded in 2008, we provide educational Multiple Sclerosis information via live seminars and via the internet.

Key-Notes: Our live seminars average approx 60 people per educational program. Our blog is visited over 2900 times per week and our website is visited by thousands each month.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in (90) Countries.

On this blog see our Directory, Archives, recent Blog Posts & so much more. Use the Blog Search box (enter a keyword). See our Facebook information AND Links to other MS Organizations & bloggers. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos and some for fun.

Disclaimer: "Stu's Views & MS News" / 'MS Views and News' does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Like this blog? - CLICK "LIKE"

Thursday, September 24, 2009

FDA News: The FDA says there have been 13 confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients taking Biogen Idec and Elan

Sept. 21, 2009 | Vol. 6 No. 183


The FDA says there have been 13 confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients taking Biogen Idec and Elan Pharmaceuticals’ Tysabri for multiple sclerosis (MS) in the past three years.

Biogen and Elan voluntarily suspended the marketing of Tysabri (natalizumab) in 2005 because of two PML brain infections in patients taking the drug.

The drug was reintroduced in July 2006 under a restricted distribution program, and from that point until Sept. 8, 13 PML cases, four of them in the U.S., were confirmed in patients taking the drug as monotherapy for MS, the FDA says in a statement.
============================================
Posted by at
Reactions: 

1 comments:

Carol Tanner said...

WOW...that's pretty scary stuff! And one of the things Sean was scared about in trying Tysabri..developing PML. Very unfortunate for those people who have to go through that.

September 25, 2009 12:40 PM

Post a Comment

Subscribe to: Post Comments (Atom)